Discovery of Tumor and Treatment Response Biomarkers

肿瘤和治疗反应生物标志物的发现

• 批准号: 10486871
• 负责人: Jennifer Jones
• 金额: $ 13.63万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10486871
• 关键词: Biological Markers; Blood Vessels; CCR; Caring; Cells; Cessation of life; Clinical; Clinical Protocols; Clinical Trials; Development; Disease; Disseminated Malignant Neoplasm; Elements; Goals; Immune; Immune response; Immunosuppression; Immunotherapy; Laboratories; Laboratory Research; Malignant Neoplasms; Mediating; Medical Oncology; Methods; Mission; Modality; Patient Care; Patient Monitoring; Patients; Protocols documentation; Publications; Quality of life; Radiation; Radiation Oncologist; Radiation Oncology; Radiation therapy; Role; Sampling; Stromal Cells; Stromal Neoplasm; Study Section; Surgical Oncology; Translational Research; Tumor Markers; United States National Institutes of Health; Unresectable; Work; clinical practice; cohesion; curative treatments; immune activation; improved outcome; individual patient; irradiation; liquid biopsy; nanobiology; neoplastic cell; patient population; predictive tools; responders and non-responders; response biomarker; response to injury; serine receptor; standard of care; tissue injury; tool; translational research program; treatment response; tumor; tumor progression

As a practicing radiation oncologist, seeking to integrate my laboratory and clinical efforts into a cohesive translational research program, I have focused my clinical practice on the care of patients with metastatic cancers, for whom radiation may be beneficial. These radiation treatments are provided in the setting of their care at NIH, which often includes treatment with some form of immune-directed therapy. This patient population is size-able, and these patients comprised nearly one third of all of the patients treated in the NIH Radiation Oncology Branch across the past two years. To best be able to determine what liquid biopsy or biofluid biomarkers correlate with responses to treatment, the translational research efforts of this project are following a two-pronged approach: 1) collaborating with medical and surgical oncology colleagues at NIH to investigate EVs as biomarkers for tumor status as part of those collaborators' existing protocols, and 2) developing new clinical protocols to capture information and samples from this patient population in a more cohesive and informative manner. Both of these approaches are supported by and provide support to the CCR's clinical translational mission and the basic scientific work ongoing in the Translational Nanobiology Section for the study of EV repertoires. The entirety of this project arises in the context of providing best available care to our patients, whether standard of care or on clinical trial, while seeking to identify better ways to tailor care for individual patients. This effort has led to publication of a number of clinical trials, ongoing progress of several additional clinical trials, and the development of multiple additional new clinical trials that will be submitted for CCR review in the upcoming year.

作为一名练习放射肿瘤学家，试图将我的实验室和临床努力整合到一个具有凝聚力的转化研究计划中，我将临床实践集中在转移性癌症患者的护理上，对辐射可能是有益的转移性癌症患者。在NIH的护理环境中提供了这些辐射治疗，其中通常包括采用某种形式的免疫定向治疗的治疗。该患者人群的大小可大，这些患者在过去两年中，在NIH辐射肿瘤学分支中接受治疗的所有患者中，将近三分之一。为了最好地确定哪种液体活检或生物流体与对治疗的反应相关，该项目的翻译研究工作是遵循两种措施的方法：1）与NIH的医学和外科手术同事合作，以将EVS作为tumor的一部分，以捕获该协作的一部分，并在NIH中调查EVS的一部分，并在该协作方面进行了一部分，并将其与该协作的一部分捕获，并捕获了该协作的一部分，并将其作为新的临床机构的一部分）和内容丰富的方式。这两种方法都得到了CCR的临床翻译任务和基础科学工作的支持，并为EV曲目研究的“转化纳米生物学”部分正在进行中。该项目的整个项目是在为我们的患者（无论是护理标准还是在临床试验中）提供最佳的可用护理的背景下，同时试图确定更好的方法来为个别患者量身定制护理。这项工作导致了许多临床试验的发布，持续的几个临床试验进展，并开发了多项其他新的临床试验，这些试验将在即将到来的一年中提交CCR审查。